Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in patients with refractory recurrent gastrointestinal and lung cancer
2541 Background: Autologous tumor cells stimulated T lymphocytes (AuTL) were generated ex vivo from peripheral blood lymphocytes (PBL) over a two week co-culturing process and they may have potential for efficacy as a cellular immunotherapy (IT) in refractory gastrointestinal and lung cancer patients (pts). We investigated the feasibility of a combination of AuTL transfer and chemotherapy (ChT) with S1or ZD1839 (Iressa) conditioning regimen in order to take advantage by both the anticancer and lymphodepleted effects for reconstruction of antitumor immune followed by AuTL transfer as well as an adoptive IT. Method: 13 patients were enrolled in a pilot clinical trial. The two administrations of AuTL were given prior to one ChT for one treatment cycle. The treatment was repeated at least three cycles with a one-week interval. The nonmyeloablative ChT regimen was based on standard dose of S-1 for pts with gastric (4 pts), colon (4 pts) or esophageal (3 pts) cancer and of ZD1839 for 2 pts with lung adenocarcinoma. AuTLs were administered 1x/2weeks using IV for lung cancer and direct injection or IA for gastrointestinal cancer. Results: The median period of treatment was over 12.6 months and median survival time is 14.8 months. Adverse events related to both of the ChT and AuTL transfer were minimal. 4 of 13 pts achieved major tumor responses (2 CR: complete regression and 2 PR: partial regression). 3 pts had progressive disease (PD). 6 pts had stable disease (SD) for over 90 days. PBLs were evaluated for cytokine production prior to treatment and after 3 treatments. After treatment, three of 4 CR/PR pts had increased IFN-g or TNF-a production. Two of 6 SD pts had high IFN-g and TNF-a responses. TGF-b1 and IL-4 secretion increased simultaneously in 3/3 PD pts. Conclusions: These results show that combination therapy of AuTL transfer and non-myeloablative ChT is a feasible option for pts with refractory cancers. Using the synergistic mechanism of IT and ChT, a more stringent clinical evaluation of AuTL transfer combined with nonmyeloablative ChT should be performed for various cancer to improve the effect of this new approach. No significant financial relationships to disclose.